Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Cadonilimab + SBRT in mCRC
NCT06551207Recruiting
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of cadonilimab in metastatic colorectal cancer (mCRC) (2 arms). Primary endpoint: Progression-free survival at 6 months. Started Aug 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06551207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06551207.